Circulating TNF Receptors 1 and 2 Predict Mortality in Patients with End-stage Renal Disease Undergoing Dialysis

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Gohda, Tomohito ^a   Maruyama, Shuntaro ^a   Kamei, Nozomu ^b   Yamaguchi, Saori ^a   Shibata, Terumi ^a   Murakoshi, Maki ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a   Ohsawa, Isao ^c   Gotoh, Hiromichi ^c   Nojiri, Shuko ^d   Suzuki, Yusuke ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^c Saiyu sok Hospital   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGED; BLOOD; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RENAL DIALYSIS; ROC CURVE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85014625559     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43520     Document Type: Article

References (43)

1. Katsiki, N., Papadopoulou, S. K., Fachantidou, A. I. & Mikhailidis, D. P. Smoking and vascular risk: are all forms of smoking harmful to all types of vascular disease? Public Health 127, 435-441, doi: 10.1016/j.puhe.2012.12.021 (2013).
2. Inaba, M. et al. Association of blood pressure with all-cause mortality and stroke in Japanese hemodialysis patients: the Japan Dialysis Outcomes and Practice Pattern Study. Hemodial Int 18, 607-615, doi: 10.1111/hdi.12156 (2014).
3. Shoji, T. et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12, 2117-2124 (2001).
4. Carlsson, A. C. et al. Soluble Tumor Necrosis Factor Receptor 1 Is Associated with Glomerular Filtration Rate Progression and Incidence of Chronic Kidney Disease in Two Community-Based Cohorts of Elderly Individuals. Cardiorenal Med 5, 278-288, doi: 10.1159/000435863 (2015).
5. Aukrust, P. et al. Tumor necrosis factor superfamily molecules in acute coronary syndromes.An Med 43, 90-103, doi: 10.3109/07853890.2010.523711 (2011).
6. Carlsson, A. C. et al. Soluble tumor necrosis factor receptor 1 (sTNFR1) is associated with increased total mortality due to cancer and cardiovascular causes-findings from two community based cohorts of elderly. Atherosclerosis 237, 236-242, doi: 10.1016/j. atherosclerosis.2014.09.005 (2014).
7. Al-Lamki, R. S. & Mayadas, T. N. TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int 87, 281-296, doi: 10.1038/ki.2014.285 (2015).
8. Speeckaert, M. M., Speeckaert, R., Laute, M., Vanholder, R. & Delanghe, J. R. Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases. Am J Nephrol 36, 261-270, doi: 10.1159/000342333 (2012).
9. Omote, K. et al. Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice. Am J Physiol Renal Physiol 306, F1335-1347, doi: 10.1152/ajprenal.00509.2013 (2014).
10. Gohda, T. et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23, 516-524, doi: 10.1681/ASN.2011060628 (2012).
11. Niewczas, M. A. et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23, 507-515, doi: 10.1681/ASN.2011060627 (2012).
12. Sonoda, Y. et al. Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy. PLoS One 10, e0122212, doi: 10.1371/journal.pone.0122212 (2015).
13. Mallamaci, F., Tripepi, G., Cutrupi, S., Malatino, L. S. & Zoccali, C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 67, 2330-2337, doi: 10.1111/j.1523-1755.2005.00338.x (2005).
14. Tripepi, G., Mallamaci, F. & Zoccali, C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16 Suppl 1, S83-88 (2005).
15. Hung, S. C., Hsu, T. W., Lin, Y. P. & Tarng, D. C. Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients. Clin J Am Soc Nephrol 7, 1257-1265, doi: 10.2215/CJN.08410811 (2012).
16. Carlsson, A. C. et al. High levels of soluble tumor necrosis factor receptors 1 and 2 and their association with mortality in patients undergoing hemodialysis. Cardiorenal Med 5, 89-95, doi: 10.1159/000371661 (2015).
17. Carlsson, A. C. et al. Soluble TNF receptors and kidney dysfunction in the elderly. J Am Soc Nephrol 25, 1313-1320, doi: 10.1681/ ASN.2013080860 (2014).
18. Niewczas, M. A. et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 4, 62-70, doi: 10.2215/CJN.03010608 (2009).
19. Neirynck, N., Glorieux, G., Schepers, E., Verbeke, F. & Vanholder, R. Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: a prospective cohort study. PLoS One 10, e0122073, doi: 10.1371/journal. pone.0122073 (2015).
20. Castillo, A., Islam, M. T., Prieto, M. C. & Majid, D. S. Tumor necrosis factor-α receptor type 1, not type 2, mediates its acute responses in the kidney. Am J Physiol Renal Physiol 302, F1650-1657, doi:10.1152/ajprenal.00426.2011 (2012).
21. Singh, P., Bahrami, L., Castillo, A. & Majid, D. S. TNF-α type 2 receptor mediates renal inflammatory response to chronic angiotensin II administration with high salt intake in mice. Am J Physiol Renal Physiol 304, F991-999, doi: 10.1152/ ajprenal.00525.2012 (2013).
22. Vielhauer, V., Stavrakis, G. & Mayadas, T. N. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 115, 1199-1209, doi: 10.1172/JCI23348 (2005).
23. Jofré, R., Rodriguez-Benitez, P., López-Gómez, J. M. & Pérez-Garcia, R. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol 17, S274-280, doi: 10.1681/ASN.2006080926 (2006).
24. Gupta, J. et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 7, 1938-1946, doi: 10.2215/CJN.03500412 (2012).
25. Lee, B. T. et al. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol 16, 77, doi: 10.1186/s12882-015-0068-7 (2015).
26. Stenvinkel, P., Heimbürger, O., Lindholm, B., Kaysen, G. A. & Bergström, J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15, 953-960 (2000).
27. Choi, D. E. et al. Pretreatment with the tumor nerosis factor-alpha blocker etanercept attenuated ischemia-reperfusion renal injury. Transplant Proc 41, 3590-3596, doi: 10.1016/j.transproceed.2009.05.042 (2009).
28. Bethunaickan, R. et al. Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation. Arthritis Rheum 64, 3399-3408, doi: 10.1002/ art.34553 (2012).
29. Taubitz, A., Schwarz, M., Eltrich, N., Lindenmeyer, M. T. & Vielhauer, V. Distinct contributions of TNF receptor 1 and 2 to TNFinduced glomerular inflammation in mice. PLoS One 8, e68167, doi: 10.1371/journal.pone.0068167 (2013).
30. Mattey, D. L., Glossop, J. R., Nixon, N. B. & Dawes, P. T. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum 56, 3940-3948, doi: 10.1002/art.23075 (2007).
31. Luna, J. M. et al. Tumour necrosis factor receptor 1 and mortality in a multi-ethnic cohort: the Northern Manhattan Study. Age Ageing 42, 385-390, doi: 10.1093/ageing/afs175 (2013).
32. Saulnier, P. J. et al. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort. Diabetes Care 37, 1425-1431, doi: 10.2337/dc13-2580 (2014).
33. Lee, J. E. et al. Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS One 8, e58007, doi: 10.1371/journal.pone.0058007 (2013).
34. Pavkov, M. E. et al. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 87, 812-819, doi: 10.1038/ki.2014.330 (2015).
35. Ng, D. P. et al. Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system. Diabetologia 51, 2318-2324, doi: 10.1007/s00125-008-1162-1 (2008).
36. Goodkin, D. A. et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14, 3270-3277 (2003).
37. Stenvinkel, P. & Lindholm, B. C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 23, 72-78, doi: 10.1159/000082014 (2005).
38. Ishii, J. et al. Multimarker approach to risk stratification for long-term mortality in patients on chronic hemodialysis. Circ J 79, 656-663, doi: 10.1253/circj.CJ-14-0915 (2015).
39. Bazeley, J. et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 6, 2452-2461, doi: 10.2215/CJN.00710111 (2011).
40. Moons, K. G., de Groot, J. A., Linnet, K., Reitsma, J. B. & Bossuyt, P. M. Quantifying the added value of a diagnostic test or marker. Clin Chem 58, 1408-1417, doi: 10.1373/clinchem.2012.182550 (2012).
41. Pencina, M. J., D'Agostino, R. B. & Vasan, R. S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27, 157-172; discussion 207-112, doi: 10.1002/sim.2929 (2008).
42. Cook, N. R. & Ridker, P. M. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures.An Intern Med 150, 795-802 (2009).
43. Park, J. et al.A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival. Kidney Int 84, 795-802, doi: 10.1038/ki.2013.237 (2013).